PHAR LLC, a United States-based boutique health care consultancy that practices health economics and outcomes research, has named Mallik Greene, BPharm, PhD, DBA as its new vice president for Health Economics and Outcomes Research, it was reported yesterday.
Dr Greene has worked in the pharmaceutical industry for nearly two decades. Working at such globally recognised pharmaceutical companies as Eli Lilly, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Otsuka, and Vertex Pharmaceuticals. Dr Greene developed and implemented successful strategies to improve brand differentiation and demonstrate value to payers, physicians and patients. His work has resulted in more than 200 peer-reviewed publications in dozens of journals and conferences, spanning a wide variety of therapeutic areas.
Dr Greene's experience and training include a degree in pharmacy, a PhD in health economics and outcomes research, post-doctoral fellowship in health economics and outcomes research and a doctorate in business administration.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients